In a regulatory filing, Green Dot Bank CEO Mary Dent disclosed the sale of 7,754 common shares of Green Dot at a price of $84.99 per share.

The Boeing Co has been awarded a maximum $217,033,045 undefinitized contractual action delivery order against a five-year base contract with one five-year option period for F/A-18 aircraft spare parts.

The Board of Directors of Westlake Chemical authorized the company to repurchase an additional $150M of shares of its common stock under its existing share repurchase program. As of August 17, 2018, approximately 6.5M shares of common stock had been acquired at an aggregate purchase price of approximately $360M under the program. After this expansion of the size of the program, and as of the same date, an aggregate of approximately $290M will be available for purchase under the program.

In a regulatory filing, Penn National Gaming CEO Timothy J. Wilmott disclosed the purchase of 100,000 common shares of the company at a price of $30.85 per share.

The dividend will be payable on September 12, 2018 to stockholders of record on August 28, 2018.

Avista Healthcare Public Acquisition Corp and Organogenesis announced that they have entered into a definitive merger agreement, under which Organogenesis will become a wholly owned subsidiary of AHPAC. Affiliates of Avista Capital Partners have agreed to invest $92M in the combined company in conjunction with the transaction. Following the closing of the transaction, Organogenesis will be listed on the Nasdaq Stock Exchange under the ticker symbol (ORGO) The combined company will have an anticipated initial enterprise value of approximately $673M. Organogenesis' mission is to provide integrated healing solutions that improve medical outcomes and the lives of patients, while lowering the overall cost of care. Organogenesis' product portfolio is designed to treat a variety of patients with repair and regenerative needs across the continuum of care. Organogenesis has over 600 employees worldwide and is led by a management team of with more than 75 years of collective regenerative medicine experience. This transaction will be funded through a combination of cash, stock, and rollover debt financing. Organogenesis' key existing shareholders will remain committed long-term partners by rolling over their equity into the combined company. The boards of directors of AHPAC and the company have unanimously approved the proposed transaction and shareholders of the company representing approximately 89% of the outstanding stock of the company have agreed to support approval of the proposed transaction in any consent solicitation or shareholders' meeting in connection with the transaction. Completion of the proposed transaction, which is expected before the end of the year, is subject to customary and other closing conditions, including regulatory approvals and receipt of approvals from AHPAC's shareholders.

MidSouth Bancorp issued the following statement in response to the letter sent to the Board of Directors of MidSouth by Jacobs Asset Management dated August 15, 2018 and filed publicly with the SEC on Schedule 13D: "MidSouth's Board of Directors welcomes open communications with all of our shareholders and appreciates their views on enhancing shareholder value. The Board will carefully review with its legal and financial advisors the letter sent by Jacobs Asset Management and remains committed to act in the best interests of all MidSouth shareholders."